CAPTRUST Financial Advisors
TAK icon

CAPTRUST Financial Advisors’s Takeda Pharmaceutical TAK Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Sell
143,998
-14,631
-9% -$242K ﹤0.01% 1227
2026
Q1 		$2.94M Buy
158,629
+39,855
+34% +$699K 0.01% 1013
2025
Q4 		$1.85M Buy
118,774
+77,670
+189% +$1.11M ﹤0.01% 1136
2025
Q3 		$602K Buy
41,104
+2,664
+7% +$39.6K ﹤0.01% 1700
2025
Q2 		$594K Buy
38,440
+2,189
+6% +$32.3K ﹤0.01% 1625
2025
Q1 		$539K Buy
36,251
+18,817
+108% +$264K ﹤0.01% 1603
2024
Q4 		$231K Sell
17,434
-6,702
-28% -$92.1K ﹤0.01% 2068
2024
Q3 		$343K Sell
24,136
-1,966
-8% -$27.9K ﹤0.01% 1807
2024
Q2 		$338K Sell
26,102
-12,000
-31% -$159K ﹤0.01% 1741
2024
Q1 		$529K Sell
38,102
-18,225
-32% -$265K ﹤0.01% 1458
2023
Q4 		$804K Sell
56,327
-3,086
-5% -$43.8K ﹤0.01% 1405
2023
Q3 		$919K Buy
59,413
+26,849
+82% +$416K ﹤0.01% 1256
2023
Q2 		$512K Buy
32,564
+1,139
+4% +$18.7K ﹤0.01% 1611
2023
Q1 		$518K Sell
31,425
-5,106
-14% -$81.3K ﹤0.01% 1387
2022
Q4 		$570K Buy
36,531
+20,573
+129% +$287K ﹤0.01% 1267
2022
Q3 		$207K Buy
15,958
+3,553
+29% +$49.4K ﹤0.01% 1802
2022
Q2 		$174K Buy
12,405
+3,971
+47% +$56.7K ﹤0.01% 1790
2022
Q1 		$121K Sell
8,434
-7,167
-46% -$105K ﹤0.01% 2128
2021
Q4 		$213K Buy
15,601
+7,881
+102% +$111K ﹤0.01% 1597
2021
Q3 		$126K Sell
7,720
-1,084
-12% -$18.2K ﹤0.01% 1888
2021
Q2 		$148K Buy
8,804
+697
+9% +$11.9K ﹤0.01% 1743
2021
Q1 		$148K Buy
8,107
+1,985
+32% +$35.7K ﹤0.01% 1693
2020
Q4 		$111K Buy
6,122
+1,918
+46% +$33.7K ﹤0.01% 1460
2020
Q3 		$74K Buy
4,204
+1,152
+38% +$21K ﹤0.01% 1485
2020
Q2 		$54K Buy
+3,052
New +$54.8K ﹤0.01% 1599

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

CAPTRUST Financial Advisors's TAK Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Takeda Pharmaceutical (TAK) stake by 9.2% in Q2 2026, selling an estimated $242K and leaving 143,998 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1227.

CAPTRUST Financial Advisors first reported a position in TAK in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.94M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • CAPTRUST Financial Advisors held 143,998 shares of Takeda Pharmaceutical worth $2.31M as of Q2 2026.
  • CAPTRUST Financial Advisors sold 14,631 Takeda Pharmaceutical shares in Q2 2026, an estimated $242K.
  • Takeda Pharmaceutical made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1227 holding.
  • CAPTRUST Financial Advisors first reported a position in Takeda Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • CAPTRUST Financial Advisors's Takeda Pharmaceutical position peaked at $2.94M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.